The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
The RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Statins Don't Increase Risk of Colchicine Myopathy
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
TREG Innovators Win the Crafoord Prize
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
The IL-6 Wars
In 1998 the biologic era came in like a lion and has been roaring since. The TNF inhibitors have dominated the market from 1999 to present and have been unopposed until the introduction of new target targeted therapies.
The RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
DMARDs Under Study for Secondary Prevention of Cardiovascular Events
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
RheumNow Week in Review – 16 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com
EULAR 2016 Recommendations on Early Arthritis
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
The RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
